|
| Press Releases |
|
 |
|
| Friday, October 25, 2024 |
|
|
HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD's The Liver Meeting 2024 |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, will present at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting, taking place from November 15-19, 2024 in San Diego, California. more info >> |
|
| Wednesday, September 11, 2024 |
|
|
EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies, Highlighting Benefits of Berberine Ursodeoxycholate (HTD1801) |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, presents at the 60th European Association for the Study of Diabetes (EASD) Annual Meeting, taking place from September 10-13, 2024 in Madrid, Spain. more info >> |
|
| Friday, June 21, 2024 |
|
|
HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801) |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the American Diabetes Association's (ADA) 84th Scientific Sessions, taking place from June 21-24, 2024 in Orlando, Florida. more info >> |
|
| Wednesday, June 5, 2024 |
|
|
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801) |
| HighTide Therapeutics, Inc. (HKEX: 2511), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced that it will make multiple presentations at the European Association for the Study of the Liver (EASL) Congress, taking place from June 5-8, 2024 in Milan, Italy. more info >> |
|
| Wednesday, January 11, 2023 |
|
|
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study) |
| HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH"). more info >> |
|
| Thursday, January 5, 2023 |
|
|
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations |
| HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases more info >> |
|
| Thursday, November 17, 2022 |
|
|
AJG Publishes Data from HighTide Therapeutics' Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis |
| HighTide Therapeutics, Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the publication of the results of their Phase 2 study of HTD1801 in adults with primary sclerosing cholangitis (PSC) in the American Journal of Gastroenterology. more info >> |
|
| Wednesday, November 16, 2022 |
|
|
American Journal of Gastroenterology Publishes Data from HighTide Therapeutics' Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis |
| HighTide Therapeutics, Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced publication of the results of their Phase 2 study of HTD1801 in adults with primary sclerosing cholangitis (PSC) in the American Journal of Gastroenterology. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
NEFECON(R) Included in National Reimbursement Drug List (NRDL)
Nov 29, 2024 22:45 HKT/SGT
|
|
|
Niyo Doubles Click-Through Rates and Improves Customer Retention with CleverTap 
Nov 29, 2024 22:40 HKT/SGT
|
|
|
Dmall Inc. Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange
Nov 29, 2024 22:30 HKT/SGT
|
|
|
Edvantage Group Announces FY2024 Annual Results
Nov 29, 2024 22:14 HKT/SGT
|
|
|
The Hong Kong Institute of Directors Announces Winners
Nov 29, 2024 21:06 HKT/SGT
|
|
|
Launch of Demonstration Test for CO2 Capture from Chemical Recovery Boilers at Paper Mills in Japan
Nov 29, 2024 19:11 JST
|
|
|
Mitsubishi Electric's Swedish Subsidiary Signs a Share Transfer Agreement to Wholly Acquire Norwegian Elevator Company ALT Heis
Nov 29, 2024 15:30 JST
|
|
|
JAL and NEC Test AI-Powered Carry-On Baggage Analysis Solution
Nov 29, 2024 15:27 JST
|
|
|
Hitachi Energy to integrate ScottishPower wind farm to power almost one million homes in the United Kingdom
Nov 29, 2024 12:54 JST
|
|
|
TGR Announces Partially Upgraded Supra (3.0-liter) and Special-edition Supra "A90 Final Edition"
Nov 29, 2024 11:22 JST
|
|
|
HEROWORKS Intensifies Collaboration with a Global Hotel IT Company
Nov 29, 2024 10:00 HKT/SGT
|
|
|
EdgePoint Infrastructure Inks Strategic Partnership with CelcomDigi to expand connectivity in Malaysia at TowerXchange Meet Up Asia 2024
Nov 29, 2024 09:30 HKT/SGT
|
|
|
Trescon's World Blockchain Summit Rebrands to HODL, Signalling a Bold New Era for Innovations in Blockchain and Beyond
Nov 28, 2024 23:26 HKT/SGT
|
|
|
Academic Labs (AAX) Selected as the Official Educational Sponsor for the 2024 World Chess Championship in Singapore
Nov 28, 2024 21:50 HKT/SGT
|
|
|
Hitachi Receives an Order for All 147 Elevators and Escalators for the Second Phase of the Taipei MRT Wanda-Zhonghe-Shulin Line
Nov 28, 2024 22:20 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
